solubility modelling

Pre-Clinical (Discovery and Development)

Novartis' Jennifer Sheng on Solubility Modelling & the Future of Solubilisation

December 10 by Andrea Charles

Poor solubility is an obvious barrier to advancing potentially efficacious drug candidates. In this interview Jennifer Sheng, Fellow at Novartis, discusses the most efficient approaches for...

Utilising Solubility Modelling to Reduce the R&D Timeline

December 24 by Pharma IQ

Reducing the time drugs take to get to market is a key focus for a pharmaceutical industry facing the expiry of patents on blockbuster products and the subsequent influx of generics. Poor solubil...

FIND CONTENT BY TYPE

Pharma IQ COMMUNITY

ADVERTISE WITH US

Reach Pharmaceuticals & Biotechnology professionals through cost-effective marketing opportunities to deliver your message, position yourself as a thought leader, and introduce new products, techniques and strategies to the market.

Advertise Now

JOIN THE Pharma IQ COMMUNITY

Join Pharma & Biotech today and interact with a vibrant network of professionals, keeping up to date with the industry by accessing our wealth of articles, videos, live conferences and more.

Pharma IQ, a division of IQPC

Careers With IQPC| Contact Us | About Us | Cookie Policy